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Abstract
Those who suffer from infertility, either due to a congenital or acquired cause and cannot or are opposed to other means, such as surrogacy or adoption, to have a child, are potential candidates for uterine transplantation. Uterine transplantation is a form of allograft
transplantation, meaning that it is a transplant of tissue from a donor who is genetically different from the recipient. Additionally, it
is a vascularized transplant, including donor blood vessels that will be sutured to the vasculature of the recipient (Testa et al. 2017).
This procedure has been attempted around the globe with varying levels of success ranging from delivery of a healthy child to
necrosis of the graft and rejection of the transplanted tissue. While there does not seem to be one specific reason that can account
for the rejection of a uterus transplant, the main factor responsible for failure is problems with arterial inflow or venous outflow in
the recipient. Other potential factors that may contribute include cervix-vaginal size differences between donor uterus and recipient,
pathology of the donated uterus, immunosuppressants, and wait time from transplant to embryo transfer. Advancements in robotic
assisted hysterectomy to procure the donor uterus, using ovarian veins instead of uterine veins for venous outflow, and deceased
donor uteri instead of living donor uteri are all promising ways that can streamline the transplant process and help transition the
experimental procedure of uterine transplantation to an accepted clinical one.
Introduction
Uterine transplantation is a procedure where a uterus
from either a live or deceased donor is surgically implanted temporarily in a recipient, in order that the recipient can carry her own child in the transplanted uterus.
The transplanted uterus is subsequently removed, either
when a baby is born, if the pregnancy is terminated due
to complications, or due to rejection of the transplant.
Uterine Transplantation is an innovative treatment for
those who are unable to carry a fetus in their own respective uteri, either due to a congenital disorder, such
as the absence of or an underdeveloped uterus, hysterectomy, due to disease, cancer, endometriosis, elective
hysterectomy, or for transgender individuals who do not
have a uterus (Testa et al., 2017). Since uterine transplantation is not considered a life-saving procedure, many are
ethically opposed to the promotion and investment into
such an experimental and costly surgery.
In this paper we will try to determine if the uterus
can be transplanted successfully with childbearing results,
and which factors are responsible for the rejection of a
uterus transplant.
Materials and Methods
The Information contained in this review was found by
searching the Touro online library general search, Ebsco,
and Proquest databases using key terms such as “uterine
transplantation.” Pubmed and Google Scholar were also
searched utilizing similar key words and phrases.
Candidates for Uterine Transplantation
People who express interest in uterus transplants generally suffer from what is known as uterine factor infertility,
UFI (Arian et al., 2017), also known as absolute uterine
factor infertility, AUI (Branstrom et al., 2020), This can be
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due to a congenital cause, such as a condition known as
Mayer-Rokitansky-Kuster-Hauser syndrome (MRKH), or
Mullerian agenesis, which is caused by the “underdevelopment of the Mullerian duct, with resultant agenesis or
atresia of the vagina, uterus, or both” (Oelschlager, 2018).
Agenesis refers to the failure during embryological development of an organ and atresia is where there is either
an obstruction to the lumen, or an opening is abnormally
narrowed. Since the Mullerian duct in utero is responsible
for the development of the uterus, fallopian tubes, cervix,
and the upper part of the vagina, when it fails to develop in MRKH, all those structures, aside from the ovaries,
are affected, and this often results in infertility. Patients
with MRKH are good candidates for uterine transplantation because they have functioning ovaries, which are
not included in the uterus transplant. Their oocytes can
be extracted for in vitro fertilization, and they can have
a biological child of their own genetics. Another class of
those who are interested in uterine transplants include
those who have absolute uterine factor infertility due to
an acquired cause which resulted in hysterectomy, such
as fibroid tumors, endometriosis, chronic pain, abnormal
bleeding, malignancy, and obstetric complications. In one
study, out of the 239 people screened, one third sought
treatment due to congenital UFI, while the other two
thirds had acquired UFI. Of the acquired group, half were
due to benign conditions, 25.3% were due to gynecologic
malignancies, and 24.7% had had prior obstetric complications that resulted in hysterectomy. Although there
were five transgender and one intersex individual, they
were not included because they did not fit the inclusion
criteria of the screening (Arian et al., 2017). In another 2017 study, candidates similarly included those with
MRKH, acquired conditions such as irreversible intrauterine adhesions, fibromas that could not be operated

Uterine Transplantation Factors Accounting for Success or Failure

on, and those who had lost their uterus from either benign or malignant pathologies or postpartum complications (Testa et al., 2017).
Donor Eligibility
Different studies had varied qualifications included in their
inclusion criteria. Firstly, age was a consideration. In one
study, age was determined to be from 40-60, though those
under the age of forty were considered if a candidate had
successful pregnancies in the past and did not want to have
another pregnancy in the future (Testa et al., 2017). Similarly,
in other studies, with successful live-birth outcomes, a 32
year old uterus was used, having borne 2 children prior to
transplantation (Testa et al., 2018), and a 24 year old nulligravid uterus was also used in successful transplantation
(Chmel et al., 2019). However, in the first successful transplant in 2014 that resulted in childbirth, a 62 year old uterus
was used, and another a successful live birth resulted from
a 63 year-old uterus at the time of birth, indicating that although older uteri are not necessarily considered ideal, they
have yielded live births. (Brannstrom et al., 2020). Since
often enough recipient’s mothers want to be donors for
their daughters, in some studies an older upper limit is given
at 55-65 years of age (Kisu et al., 2018).
Additional donor requirements in some studies included criteria such as testing negative for gonorrhea, chlamydia, syphilis and HPV, or previous vaccination against
HPV. Previous history of HSV-2 was considered if there
were no current symptoms, and previous HPV was considered as long as a negative history was shown since
the case of HPV. Last, one prior full-term live birth was a
qualification (Testa et al., 2017).
Other requirements included normal-shaped uteri,
proper perfusion through uterine vasculature, and the absence of uterine damage or disease (Chmel et al., 2019).
Nulliparous, Nulligravid, or Multiparous Donor Uterus
In choosing between a nulligravid uterus, one that has
never carried a fetus, a nulliparous uterus, a uterus that has
never born offspring, and a multiparous uterus, one that
has born offspring, different studies included multiparity in
the inclusion criteria while others did not. According to a
2019 study using a nulliparous deceased donor, nulliparity
was considered an advantage in terms of graft recovery because the uterine veins and arteries were straight and not
varicose, as opposed to what they noted with multiparous
donors (Chmel et al., 2019). However, that was an observation made using few subjects, and would need to be
further investigated to determine if a significant difference
between the straightness of vasculature exists between
nulliparous and multiparous uteri.

Live vs. Deceased Donor
Before investigating the differences between a living as
opposed to a deceased donor, it is important to define
who is considered “deceased.” In this paper, deceased is
used to mean brain-dead.
There are certain advantages to using a deceased
donor over a live donor. Firstly, using a live donor to
procure a graft includes certain risks associated with any
surgical procedure, such as the use of anesthesia, and surgery, and specifically possible urological, psychological or
sexual dysfunction that may result, which are not considerations that need to be taken with a deceased donor.
Secondly more radical surgical dissection can be done
using a deceased donor than a live donor, which enables
surgeons to procure larger vessels, decreasing the risk
of graft thrombosis. Additionally, a longer vaginal cuff can
be procured from a deceased donor, allowing a better
vaginal–vaginal anastomosis between the donated uterus
and the recipient’s vagina (Chmel et al., 2019).
A clear disadvantage of using a deceased donor is the
practicality; the nature by which deceased donor uteri
become available is unpredictable. Also, multidisciplinary
teams and the recipient must go to the location of the
donor. Moreover, in many countries, physicians have less
access to deceased vascularized composite allografts, and
there is more restricted access to deceased donor uteri
due to the complicated nature of surrogate consent if the
deceased has not expressly stated the desire to donate
before death (Chmel et al., 2019).
However, new innovations in procurement of the donor
uterus, such as using robotically-assisted minimally invasive
procedures, can likely decrease risks to live donors by minimizing tissue trauma and bleeding compared to open surgery, which would favor using live donor uteri (Brannstrom
et al., 2020). In one minimally invasive, robotic surgery, the
estimated blood loss of the donor was 400 mL, compared
to the researchers previous surgeries using laparotomy in
nine cases, which ranged from estimated blood loss values between 300-2400 mL, with an average of 920 mL
(Brannstrom et al., 2020). Using robotic technology can
also provide more dexterity and seven degrees of freedom for the surgeon, not to mention micro-suturing can
be done more efficiently through laparoscopic ports (Wei
et al., 2017). Also, minimally invasive robotic procedures
can minimize both surgery and recovery time for the
donor (Carbonnel et al., 2020). Surgery time in one robotic assisted surgery took 6 hours, which is the shortest
surgery duration time recorded for uterus procurement
for transplant. That may be partially due to the choice of
vasculature that the researchers procured with the graft,
but nonetheless they were able to drastically reduce
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surgical time (Wei et al., 2017). In addition to a reduction
in bleeding and trauma, minimally invasive surgery yields
better cosmetic results, which may influence a candidate’s
readiness to donate (Carbonnel et al., 2020).
Steps involved in Uterine Transplantation
The process of uterine transplantation can be summarized briefly, according to Testa, et al., as follows. First,
the successful transplantation of the graft, including perfusion, or blood flow through the grafted vasculature,
and the assessment of vital tissue present on the cervix
in cervical biopsy to determine if the tissue is accepted
by the recipient. Next, a normal menstrual cycle should
result, which means that the grafted uterus is responding
to the recipient’s hormones. Stable immunosuppression,
suppression of the recipient’s immune system toward the
foreign uterus should be maintained. Once immunosuppression is achieved, a fertilized ovum is implanted. After
implantation that results in pregnancy, the last step is the
successful delivery of a hopefully healthy child. At any of
these steps, complications can occur that would result in
the failure of the uterine transplant (Testa et al., 2017).
Removing the donor uterus can be done through either
laparotomy or laparoscopy. In a 2017 clinical trial on five
individuals, the laparotomic removal of the donor uterus
is detailed. The hysterectomy performed on the donor,
however, is more complicated than a regular hysterectomy, due to the vasculature that needs to be connected
to the recipient to allow graft inflow and outflow in the
recipient. To allow that, the vascular pedicles, tissues containing the arteries and veins of the donor uterus, were
dissected completely. The arterial vascular pedicle of the
graft included the uterine artery, which supplies blood
flow to the uterus, and a part of the internal iliac artery.
The graft uterus was drained by the uterine and utero-ovarian veins, located between the uterus and ovary.
A transverse cut was made below the cervix, in order to
obtain a cuff that could sufficiently be anastomosed to the
upper vagina of the recipient.After removal, arteries were
reconstructed, when needed, through microvascular surgery (Testa et al., 2017).
As for the recipient, the external iliac artery and the
external iliac vein were dissected and the internal iliac artery patch of the donor was grafted to the external iliac
artery of the recipient. For venous outflow, the uterine or
utero-ovarian vein, depending on which provided better
venous outflow, was sutured to the external iliac vein of
the recipient. Once blood flow was reperfused, the cervix
of the new uterus was connected to the vaginal vault of the
recipient. Blood flow was subsequently monitored by a
doppler blood flow monitor to assess arterial inflow to the
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transplanted uterus. Postoperatively, for the first five days
Doppler ultrasounds were performed, cervical biopsy was
done on the fifth day, MRI of the uterus was performed to
evaluate blood flow, and cervical examination under anesthesia was done to determine if rejection of the transplant
tissue occurred. To suppress the immune response of the
host to the allograft, immunosuppressive drugs such as thymoglobulin, tacrolimus, mycophenolic acid, and a steroid
taper were administered (Testa et al., 2017).
Vasculature Involved
The common iliac artery bifurcates into the internal and
external iliac arteries. A branch of the internal iliac artery
is the uterine artery, which supplies blood flow to the
uterus. Blood flow from the uterus is via the uterine
veins, internal iliac veins, inferior vena cava, and to the
heart. Figure 1 shows a diagram of the vasculature where
blood vessels attached to the allograft are connected
slightly differently in the recipient than expected. At point
A, the uterine artery, with a branch of the internal iliac
from the donor is anastomosed to the external iliac artery, instead of the recipient’s own internal iliac artery. At
point B, the uterine vein of the donor uterus is attached
to the external iliac vein of the recipient, instead of the
internal iliac vein.
One of the most difficult parts of uterus transplantation is securing a good venous outflow. In most cases,
the uterine veins are used, which often have thin walls,
can vary in number, and often are not shown sufficiently
in preoperative imaging. During surgery, their dissection
can be tedious, can increase the risk of bleeding, and increases surgery time (Testa et al., 2018). Moreover, the
uterine vein has multiple branches and is close to the

Figure 1.This schematic diagram portrays the blood vessels
supplying and draining the allograft uterus. Point A is the
anastomosis of the uterine artery to the external iliac artery. Point
B is the anastomosis of the donor uterine vein to the external iliac
vein (Testa et al., 2017).
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ureter, which could result in accidental bleeding or injury to the ureter (Carbonnel et al., 2020). In one 2018
successful trial, researchers sustained an allograft through
the utero-ovarian veins alone, without uterine veins. The
researchers recommended using the utero-ovarian veins
instead of the uterine veins, which are easier to identify,
dissect, and provide for safer surgery on the part of the
donor. In another clinical trial, the proximal portions of
the utero-ovarian veins were dissected as potential extra
venous outflow, and ended up being used along with the
uterine veins as well, due to the thinness of the uterine
veins of the donor (Brannstrom et al., 2020). Further, by
using the utero-ovarian veins instead of uterine veins, a
robotic laparoscopic approach is more feasible, which will
again increase the safety and ease for the donor (Testa et
al., 2018). Also, the ovarian veins are more distant from
the ureter, so surgeons will not be concerned about inadvertent damage to them (Carbonnel et al., 2020). There
can, though, be negative repercussions for the donor associated with using the ovarian veins as venous outflow.
In transplant procedures done in both India and China,
removal of the ovarian veins required bilateral oophorectomy, removal of the ovaries. The donor women were
premenopausal, which increases their risk of morbidity
and mortality (Brannstrom et al., 2020). However, using
ovarian veins for venous outflow still need to be further
researched in the future to determine whether uterus
outflow can in all cases be sufficiently maintained using
the ovarian veins alone (Carbonnel et al., 2020).
Wait Time Between Transplant and Surgery
Common convention for many of the different uterus transplant trials has been to wait one year between
transplantation and attempt at pregnancy, similar to
other solid organ transplants. In a 2019 study, for example, embryo transfers were done starting at least 12
months post-transplant, and were done in months 13,
16, 19, and 23, until the last transfer resulted in clinical
pregnancy (Chmel et al., 2019). This convention arose
out of a recommendation from the American Society of
Transplantation which suggested that recipients of organ
transplants wait one year between the transplant and
conception to decrease any risks that may result, such as
acute rejection to the recipient, infection that could harm
the fetus, immunotherapy that could potentially be toxic
to the fetus, and to be sure that the allograft is functioning
properly (Johanesson et al., 2019).
However, women who receive uterus transplants
are generally healthy individuals whose surgical recovery should resemble that of any surgical intervention.
There is no reason to believe that tissue healing would

be impaired, and immunosuppression does not seem to
hinder tissue healing (Testa et al., 2018). Further, a uterine
transplant, unlike other organ transplants, is not meant to
be a long-term functioning transplant. Its longevity is for
about five years and for a maximum of two pregnancies
(Johanesson et al., 2019). Some suggest that there is no
scientific basis for waiting a year between transplant and
embryo transfer, especially because immunosuppression
must be terminated as soon as possible, to avoid renal
failure, which could be a risk of long-term immunosuppression. Decreased time on immunosuppressants also
reduces costs and decreases waiting time for the recipient to give birth to her baby. In their clinical trial, embryo
transfer was done before the six month post surgery
mark, and yielded successful results (Testa et al., 2018).
To provide a groundwork for the amount of time to be
waited, researchers laid down conditions to be met in the
recipient, which if achieved, should be a signal to begin
embryo transfer, as opposed to giving a generalized time
recommendation for all uterine transplant procedures.
The patient criteria are given in order as follows. First,
graft function should be stable. An indication of graft stability would be menstruation, as it is a sign that the foreign
uterus is responding to the recipient’s hormones. Next,
the absence of any acute rejection, which is determined
via cervical biopsy. Finally, stable immunosuppression
achieved with low teratogenic, or carcinogenic, risk, and
the recipient is at low risk for opportunistic infection,
which is generally associated with those who undergo
transplantation. Once these conditions are met, embryo
transfer should begin as soon as possible, even as early
as three months post-transplant if the recipient is ready
(Johanesson et al., 2019).
Complications in Pregnancy and Post-Operatively
Generally, pregnancies resulting from uterine transplantation do not reach full-term. However, many studies have
been successful in which participants have carried close
to term. In the first successful clinical study in Sweden,
mean delivery for the six patients was at 35 weeks gestation. Besides the difficulty in reaching full term, there
are some other pregnancy complications that have arisen. Some patients from the previously mentioned study
experienced preeclampsia. It is possible though, that the
preeclampsia, preterm delivery, and delivery by cesarean
section may be related to the original infertility; MRKH
sometimes presents with renal defects, such as having
a solitary kidney, which could cause extra stress to the
recipient during pregnancy, and has been generally associated with higher risk for preterm delivery, preeclampsia,
and cesarean section (Kisu et al., 2018).
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Other major complications that have arisen post-operatively in recipients include urinary tract infections, thrombosis, and hematoma. The risk of thrombosis is because
the vessels that are anastomosed are generally narrower
and can get obstructed more easily than vessels attached in
other organ transplants. Hematoma could be the result of
inadequate hemostatic processing, or cessation of bleeding. Care must be taken with re-bleeding from capillaries
that are unligated or bleeding from the vaginal cuff (Kisu
et al., 2018). Also, in one particular clinical study, vaginal
stenosis, vesicovaginal fistula, herpes, and cytomegalovirus
were complications experienced by some of the recipients.
Vesicovaginal fistulae can occur more frequently in patients
with MRKH who have a neovagina, which is constructed
due to an underdeveloped or absent vagina, and which
needs to be separated from the bladder during surgery.
This could lead to a fistula, or an opening between the
bladder and vagina (Kisu et al., 2018).
Immunosuppressants During Pregnancy
Since the transplanted uterus is from a foreign donor,
the recipient needs to be on immunosuppressive drugs
to prevent her own immune system from mounting a
response against the uterus. There have been different
recommendations as to the type of drug, based on trials
from both pregnant women on immunosuppressants due
to uterus transplants and other organ transplants. The
importance here is that the immunosuppressive drug
should not be toxic to the developing fetus. Therefore
care must be taken to either prescribe immunosuppressants that are not fetotoxic, or at least halt fetotoxic
immunosuppressants when the uterus recipient begins
embryo transfer. One immunosuppressive drug that has
been implicated in spontaneous abortion in the first
trimester and congenital abnormalities of the fetus is
mycophenolate salts, which come in two different prodrugs, mycophenolate mofetil and mycophenolate sodium,
that release the compound mycophenolic acid. The FDA
classifies this drug as a Category D drug, meaning that
there is evidence that it can cause risk to the fetus during
pregnancy (Ponticelli et al., 2018). Therefore, if it is used
following the transplant, there must be a waiting period
afterward before embryo transplant begins. In one uterine transplant trial, mycophenolate mofetil was taken out
entirely from the maintenance immunosuppression to
decrease the time exposed to toxic medications for the
fetus. They were thus able to expedite the waiting time
before embryo transfer. Another drug, thymoglobulin,
is considered a category C drug, meaning it is currently unknown if risk exists to the fetus. Therefore, there
should also be a wait time between pregnancy and usage
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of thymoglobulin in immunosuppressive therapy. Other
common immunosuppressants such as corticosteroids,
azathioprine, and calcineurin inhibitors appear to be safe
in doses prescribed for transplant recipients and are
not associated with increased risk of congenital defects
(Johanesson et al., 2019).
Reasons for Rejection of Transplanted Uterus
Although in some cases there is not a clear reason why
the graft failed and rejection occurred, different studies
have hypothesized reasons for the difference in outcome.
A conclusion was that uterus pathology and venous outflow were largely responsible for three graft failures that
occurred. The authors explained that assessment of vasculature preoperatively could be improved. Thus, imaging
could be used to eliminate uteri with vasculature that is
unsuitable for a uterus transplant. They explain that using
a CT angiogram, while helpful in showing arterial blood
flow, was not sufficient in their study to tell the length and
diameter of veins.This was significant because a large part
of the donor hysterectomy surgery time was spent in dissection of the uterine vein, which can taper into thinner
tributaries where it joins with the internal iliac vein, even
though it may appear satisfactory near the uterine body.
The researchers concluded that MRI with venous phase
would have been a better choice in imaging to view the
uterine veins (Testa et al., 2017). Similarly, the researchers explained that the arterial vasculature was not of the
expected quality; in some patients arterial pathology was
present. In the preoperative imaging, the vessels appeared
patent, however; in the three grafts that failed in their
study, there was severe arterial disease present. In one
donor specifically there was thickening that resulted in
over a fifty percent decrease in luminal size. Additionally,
the researchers noted that in the first two of the five
patients studied there was a downward kinking of the
vein if the anastomosis was to the superior aspect of the
host external iliac vein. In the other three patients they
switched the venotomy position of the external iliac vein
to the medial aspect to avoid kinking. Further, the researchers observed that procuring a patch of the internal
iliac with the uterine vein provided a vessel with thicker
and stronger walls.
Another potential reason that contributed to the failure
of one of the transplants was the variation in size between
the large cervix size of the donor and small size of the vaginal vault of the recipient, which made it difficult for vaginal anastomosis. The researchers believed that the limited
space, due to the larger cervix size contributed to the graft
congestion, poor venous outflow, and pathologies present
ultimately resulted in transplant rejection (Testa et al., 2017).
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As far as immune-system induced rejection, ostensibly,
since the uterus carries a non-self, it would appear that
pregnant uterus should have some immune tolerance.
However, cervical biopsies have shown rejection in some
cases post-operatively. In one transplant study, 13 out of
163 cervical samples taken from seven patients showed
mild rejection after transplantation. Steroid therapy helped
patients reach remission, yet some developed rejection
complications again during pregnancy, which is more difficult to manage and measures need to be developed for
the future for treatment-resistant rejection. Some suggest
that the contact that the uterus has with the external environment, through the vagina, is responsible for the prospect of rejection of the allograft (Kisu et al., 2018).
Ethical Implications
The practice of uterine transplantation is a subject of
great ethical controversy. As a non-life-saving procedure,
it differs from other forms of organ transplantation, which
are considered essential. However, there are those who
categorize it similarly to face, hand, or other vascularized
transplants, which though not life-saving transplants, are
nonetheless justifiable organ transplants for improving
the quality of life of recipients. Additionally, although
uterine transplantation is considered an elective treatment, it stands as the only medical treatment for absolute uterine factor infertility. Surrogacy and adoption are
options for women with infertility, but for some women
they are not adequate substitutes for the experience of
pregnancy (Bayefsky and Berkman, 2016).
Once uterine transplantation transitions from an experimental procedure to a common clinical one, there
are multiple points that will need to be taken into consideration. There will likely be a shortage of uteri for
donation. While there are those who argue that uteri
from women who have had hysterectomies should be
used to supply organs for uterine transplants, often hysterectomies are done to remove unhealthy uteri, and
are done in a way that does not leave the organ fit for
transplantation, so those would not be feasible sources of
uteri. Uterine transplants must also come with sufficient
vasculature, which is generally not removed in an average
hysterectomy. Given that there will likely be a greater demand than the supply of uteri, there will need to be a way
to prioritize some individuals over others. As far as for
other organ transplants, such as heart, kidneys, or lungs,
pediatric or younger individuals are generally prioritized
over older adults, because adults have experienced childhood, and pediatric patients, if not given the transplant,
may never have that experience. In the same vein, it is
sensible to say that when prioritizing women for uterine

transplants, women who are of childbearing age should
be given precedence over both women who are older
and beyond reproductive age and adolescents who have
not yet reached childbearing age. However, in choosing
between younger and older individuals within the span of
child-bearing, women who are nearing the end of their
childearing years should be given priority over younger
individuals so that they can have their chance to have
children before they age out of their childbearing years,
while the younger individuals still have time. “Normal
childbearing age” is considered between the ages of
15-49 according to the World Health Organization, and
a standard for recipients should be within those limits. A
national standard, in limiting the age of recipients, should
reflect medical assessment of the surgical and obstetric
risks incurred to women of different ages, the risk to the
fetus, and the probability of successful pregnancy.
Further, there must also be some sort of child-rearing
capacity standard created that potential candidates will
demonstrate before allocating a uterus, similar to how
women who wish to adopt must meet certain criteria.
In differentiating between women with uterine infertility, different candidates have different needs with regard
to treatment. Some need only a transplant, while others
may need IVF, egg donation, or sperm donation. It is reasonable to suggest that those with the least interventions
necessary to achieve pregnancy should be given priority,
in the same vein as choosing candidates for transplantation who are more likely to have successful transplantation (Bayefsky and Berkman, 2016).
Putting aside the controversy associated with candidates for treatment, there is also dispute about the
source for donor uteri. Procuring a uterus from a live
donor can incur risk to the individual. While there are
innovations to the process of securing a uterus, through
laparoscopic robotic procedures, as opposed to open laparotomy, advancements will need to be made to decrease
the risks for the donor. Also, the advancement of using
cadaveric or nonliving donor uteri will be important in
fueling the future of uterine transplantation, though it will
be a source of contention as to whether a person who
has lost all brain function and is considered “brain dead,”
will be categorized as deceased along with those whose
circulatory and respiratory systems have failed.
Conclusion
Uterine Transplantation is a possible radical and innovative surgical option for those who suffer from absolute
uterine factor infertility. Many studies have been done
world-wide, which have contributed to the available data
on the risks and ways to improve the process. While
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there is no one factor that contributes to the rejection
or success of a uterine transplant, certain factors have
been implicated in the reasons for transplant failure or
success. Vasculature problems can account for some
reasons for rejection, such as sclerotic vessels, or using
thin-walled uterine veins that are difficult to dissect and
may not provide adequate venous outflow. Adequate imaging should be done to identify vessel pathology and the
acceptability of the donor vasculature. The possibility
of using the utero-ovarian veins might be a good alternative to the uterine veins, though it can cause the onset
of menopause and may increase morbidity in premenopausal women, due to oophorectomy. Also, mismatch in
vaginal-cervix size between the donor and recipient may
be problematic. Wait time between transplant and embryo transfer and immunosuppressants are other factors
to take into account. Advances in using deceased donor
uteri, which allows harvesting longer length of vessels, or
using live donor uteri procured through laparoscopic robotic assisted hysterectomy can streamline the process.
Although a promising treatment for those with absolute
infertility, more research needs to be conducted to ensure its safety and to standardize the procedure.
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